Anupma Nayak
Overview
Explore the profile of Anupma Nayak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
648
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Shah J, Pueschl D, Wubbenhorst B, Fan M, Pluta J, DAndrea K, et al.
Nat Commun
. 2022 Nov;
13(1):6728.
PMID: 36344544
Recurrence is a major cause of death among BRCA1/2 mutation carriers with breast (BrCa) and ovarian cancers (OvCa). Herein we perform multi-omic sequencing on 67 paired primary and recurrent BrCa...
12.
Nandi A, Debnath R, Nayak A, To T, Thacker G, Reilly M, et al.
Cancer Res
. 2022 Aug;
82(20):3718-3733.
PMID: 36007109
Dll1+ breast cancer cells activate Notch signaling in cancer-associated fibroblasts that increases Wnt ligand secretion and leads to β-catenin-driven radioresistance and metastasis, opening new therapeutic avenues for breast cancer.
13.
Kraya A, Maxwell K, Eiva M, Wubbenhorst B, Pluta J, Feldman M, et al.
JCO Precis Oncol
. 2022 Feb;
6:e2100159.
PMID: 35201851
Purpose: Ovarian cancers can exhibit a prominent immune infiltrate, but clinical trials have not demonstrated substantive response rates to immune checkpoint blockade monotherapy. We aimed to understand genomic features associated...
14.
Adekeye A, Agarwal D, Nayak A, Tchou J
J Surg Res
. 2021 Dec;
271:154-162.
PMID: 34920330
Background: The COX/prostaglandin (COX/PG) pathway plays a role in cancer pathogenesis via the production of prostaglandin E2 (PGE2). In breast cancer, the expression patterns of the COX/PG pathway enzymes involved...
15.
Budina A, Farahani S, Lal P, Nayak A
Arch Pathol Lab Med
. 2021 Dec;
146(9):1131-1139.
PMID: 34871364
Context.—: Despite continued surveillance and intravesical therapy, a significant subset of patients with lamina propria-invasive bladder cancer (T1) will progress to muscle-invasive disease or metastases. Objective.—: To analyze the value...
16.
Verbus E, Rossi A, Clark A, Taunk N, Nayak A, Hernandez J, et al.
Ann Surg Oncol
. 2021 Nov;
29(3):1530-1532.
PMID: 34783947
No abstract available.
17.
Luo X, Preciado C, Nayak A, Schwartz L, Guzzo T, Williamson S, et al.
Int J Surg Pathol
. 2021 Sep;
30(3):300-306.
PMID: 34488464
Here we report a case of renal oncocytoma in a 68 year-old male. The diagnosis was initially made on a needle biopsy 6 years prior to the partial nephrectomy. The...
18.
Hamalian S, Guth R, Runa F, Sanchez F, Vickers E, Agajanian M, et al.
Oncogene
. 2021 Jul;
40(33):5224-5235.
PMID: 34239043
Intercellular mechanisms by which the stromal microenvironment contributes to solid tumor progression and targeted therapy resistance remain poorly understood, presenting significant clinical hurdles. PEAK1 (Pseudopodium-Enriched Atypical Kinase One) is an...
19.
Schmidt H, Zhaveri S, Valente C, Pisapati K, Pickholz E, Weltz S, et al.
Breast J
. 2021 Jan;
27(2):120-125.
PMID: 33393166
Improved imaging and neoadjuvant chemotherapy (NAT) have led to higher pathologic complete response rates (pCR) in patients with invasive breast cancer. This has questioned the necessity of surgery and axillary...
20.
Goldbach M, Hoffman D, Burkbauer L, Nayak A, Tchou J
Am Surg
. 2020 Aug;
86(12):1684-1690.
PMID: 32845724
Background: Adenoid cystic breast carcinoma (ACC) is a rare subtype of triple-negative breast cancer. We aim to characterize the treatment patterns and clinical outcomes of women diagnosed with ACC at...